Trial of Surufatinib Combined With JS001 in the Treatment of Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2021-12-20
Target enrollment:
Participant gender:
Summary
This is an open-label, phase I study evaluating safety, tolerability, pharmacokinetics and
efficacy of Surufatinib combined with the humanized anti-PD-1 antibody JS001 in patients with
solid tumors.